Generics Bulletin Managing Editor Dave Wallace has nearly 10 years experience of reporting on the global generic, biosimilar, value-added and OTC medicines industries. Bringing his background and education in law to bear on industry litigation - as well as national legislative and regulatory affairs - he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and judges the annual Global Generics & Biosimilars Awards. A French speaker, Dave enjoys music - with a love of the piano - and visual arts.
Latest From David Wallace
Aspirin led the generics with the fastest-rising UK prices in June, according to the latest figures from WaveData.
Litigation involving Teva has been selected as a “bellwether” case, making it a priority for trial as part of the ongoing US investigation into generic price-fixing.
At a Medicines for Europe webinar on learning lessons from the COVID-19 pandemic, a clear consensus emerged that a continued co-ordination between industry, regulators and the European Commission was key to both effectively address the current crisis and ensure a greater level of preparedness for similar challenges in future.
The UK’s CMA has reiterated its belief that Advanz Pharma charged excessive and unfair prices for liothyronine in the UK, following a separate ruling that provided detailed guidance on how such matters should be evaluated.
Increased uptake for generics and biosimilars must become Belgium’s “new normal” in the wake of the coronavirus crisis, local off-patent industry association Medaxes has argued.
Australia has reaped the rewards of outreach efforts on biosimilars, according to the country’s GBMA off-patent industry association, with the market share enjoyed by biosimilar medicines rising significantly in the two years since Australia’s government issued a grant for educational activities. In future, the GBMA’s Biosimilar Awareness Week could be used as the model for a global biosimilars campaign backed by the IGBA.